The development of new chemotherapeutic agents

Anti-Cancer Drugs

Volumn 7, Issue SUPPL. 2, 1996, Pages 29-32

  Hanauske, A R ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

CPT 11; gemcitabine; LY231514; raltitrexed (Tomudex ); trimetrexate

Indexed keywords

ANTINEOPLASTIC AGENT; DOCETAXEL; FLUOROURACIL; GEMCITABINE; INTERLEUKIN 12; IRINOTECAN; NEW DRUG; PACLITAXEL; PEMETREXED; RALTITREXED; RETINOL; THROMBOCYTE FACTOR 4; THYMIDYLATE SYNTHASE INHIBITOR; TRIMETREXATE; VITAMIN D DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONFERENCE PAPER; DRUG DEVELOPMENT; HUMAN; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL;

EID: 0029815242     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199608002-00008     Document Type: Conference Paper

References (39)

1. Rinaldi D, Burris H, Dorr F, et al. A Phase I evaluation of LY 231514 administered every 21 days, utilizing the modified continual reassessment method for dose escalation [abstract]. Proc Am Soc Clin Oncol 1995; 14: 474.
2. Cunningham D, Zalcberg J, Francois E, et al. Tomudex (ZD 1694) a new thymidylate synthase inhibitor with good antitumor activity in colorectal cancer (ACC) [abstract]. Proc Annu Meet Am Soc Clin Oncol 1994; 13: 199.
3. Clarke SJ, Ward J, de Boer M, et al. Phase I study of the new thymidilate synthase inhibitor tomudex (ZD 1694) in patients with advanced malignancy [abstract]. Ann Oncol 1994; 5 (suppl 5): 132.
4. Zalcberg J, Cunningham D, Green M, et al. The final results of a large phase II study of the potent thymidylate synthase (TS) inhibitor tomudex (ZD 1694) in advanced colorectal cancer [abstract]. Proc Am Soc Clin Oncol 1995; 14: 204.
5. Cunningham D, Zalcberg J, Smith IE, et al. Tomudex: A novel thymidilate synthase (TS) inhibitor with clinical antitiumor activity in a range of solid tumours [abstract]. Ann Oncol 1994; 5 (suppl 8): 179.
6. Pazdur R, Casper E, Meropol N, et al. Tomudex (ZD 1694) in patients (pts) with advanced pancreatic cancer: results of phase II trial [abstract]. Proc Annu Meet Am Soc Clin Oncol 1994; 13: 207.
7. Cunningham D, Zalcberg JR, Rath U, et al. 'Tomudex' (ZD 1694): results of randomized trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia. Eur J Cancer 1956; 31A: 1945-1954.
8. Rhee MS, Balinska M, Bunni M, et al. Role of substratedepletion in the inhibition of thymidylate biosynthesis by the dihydrofolate reductase inhibitor trimetrexate in cultured hepatoma cells. Cancer Res 1990; 50: 3979-3984.
9. Marshall JL, DeLap RJ. Clinical pharmacokinetics and pharmacology of trimetrexate. Clin Pharmacokinet 1994; 26: 190-200.
10. Grem JL, King SA, Costanza ME, Brown TD, Hypersensitivity reactions to trimetrexate. Invest Neu'Drugs 1990; 8: 211-214
11. Allegra CJ, Jenkins J, Weiss RB, et al. A Phase I and pharmacokinetic study of trimetrexate using a 24-hour continuous-injection schedule. Invest New Drugs 1990; 8: 159-166.
12. Bertino JR. Folate antagonists: toward improving the therapeutic index and development of new analogs. J Clin Pharmacol 1990; 30: 291-295.
13. Sorensen JB. Treatment of non-small cell lung cancer: new cytostatic agents. Lung Cancer 1993; 10: 173-187.
14. Gesme DH Jr, Jett JR, Schreffler DD, et al. A randomized phase II trial of amonafide or trimetrexate in patients with advanced non-small cell lung cancer. A trial of the North Central Cancer Treatment Group. Cancer 1993; 71: 2723-2726.
15. Fossella FV, Winn RJ, Holoye PY, et al. Phase II trial of trimetrexate for unresectable or metastatic non-small cell bronchogenic carcinoma. Invest New Drugs 1992; 10: 331-335.
16. Dawson NA, Costanza ME, Korzun AH, et al. Trimetrexate in untreated and previously treated patients with metastatic breast cancer: a Cancer and Leukemia Group B study. Med Pediatr Oncol 1991; 19: 283-288.
17. Scher HI, Curley T, Geller N, et al. Trimetrexate in prostatic cancer: preliminary observations on the use of prostatespecific antigen and acid phosphatase as a marker in measurable hormone-refractory disease. J Clin Oncol 1990; 8: 1830-1838.
18. Witte RS, Elson P, Khandakar J, Trump DL. An Eastern Cooperative Oncology Group phase II trial of trimetrexate in the treatment of advanced urothelial carcinoma. Cancer 1994; 73: 688-691.
19. Moore M, Andersen J, Burris H, et al. A randomized trial of gemcitabine (GEM) versus 5FU as first line therapy in advanced pancreatic cancer [abstract]. Proc Am Soc Clin Oncol 1995; 14: 199.
20. Moore M. Improvements in survival and clinical benefit with the use of gemcitabine (GEM) as first-line therapy for advanced pancreatic cancer: a randomized trial [abstract]. Eur J Cancer 1995; 31A (suppl 5): S116.
21. Slichenmyer WJ, Von Hoff DD. New natural products in cancer chemotherapy. J Clin Pharmacol 1990; 30: 770-788.
22. Kaneda H, Nagata H, Furuta T, Yokokura T. Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse. Cancer Res 1990; 50: 1715-1720.
23. Bissery MC, Mathieu-Boue A, Lavelle F. Preclinical evolution of CPT-11, a camptothecin derivative [abstract]. Proc Am Assoc Cancer Res 1991; 32: 402.
24. Abigerges D, Chabot GG, Armand JP, et al. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. J Clin Oncol 1995; 13: 210-221.
25. Armand JP, Ducreux M, Mahjoubi M, et al. CPT-11 (Irinotecan) in the treatment of colorectal cancer Eur J Cancer 1995; 31 A: 1283-1287.
26. Conti JA, Kemeny N, Saltz L, et al. Irinotecan (CPT-11) is an active agent in untreated patients (pts) with metastatic colorectal cancer (CRC) [abstract]. Proc Am Soc Clin Oncol 1994; 13: 195.
27. Pitot HC, Wender D, O'Connell MJ, Wieand HS, Mailliard JA. A phase II trial of CPT-II (irinotecan) in patients with metastatic colorectal carcinoma: a North Central Cancer Treatment Group (NCCTG) [abstract]. Proc Am Soc Clin Oncol 1994; 13: 197.
28. Rothenberg ML, Eckardt JR, Burris HAT, et al. Irinotecan (CPT-11) as second line therapy for pts with 5-FU-refractory colorectal cancer [abstract]. Proc Am Soc Clin Oncol 1994; 13: 198.
29. Shimada Y, Yoshino M, Wakui A, et al. Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. J Clin Oncol 1993; 11: 909-913.
30. Fukuoka M, Niitani H, Suzuki A, et al. A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small cell lung cancer. J Clin Oncol 1992; 10: 16-20.
31. Negoro S, Fukuoka M, Niitani H, et al. A phase II study of CPT-11, a camptothecin derivative, in patients with primary lung cancer. CPT-11 Cooperative Study Group. Gan To Kagaku Ryoho 1991; 18: 1013-1019.
32. Fujita A, Takahatake H, Tagaki S, Sekine K. Pilot study of irinotecan in refractory small cell lung cancer. Gan To Kagaku Ryoho 1995; 22: 889-893.
33. Masuda N, Fukuoka M, Takada M, et al. CPT-11 in combination with cisplatin for advanced non-small cell lung cancer. J Clin Oncol 1992; 11: 1775-1780.
34. Takeuchi S, Dobashi K, Fujimoto S, et al. A late phase II study of CPT-11 on uterine cervical cancer and ovarian cancer. Research Groups of CPT-11 in Gynecologic Cancers. Gan To Kagaku Ryoho 1991: 18: 1681-1689.
35. Chevallier B, Lhomme C, Dieras V, et al. Phase II trial of CPT-11 in advanced cervical carcinoma [abstract]. Proc Amer Soc Clin Oncol 1995; 14: 267.
36. Kavanagh JJ, Kudelka AP, Edwards CE, et al. CPT-11 (irinotecan): phase II study in refractory squamous cell carcinoma of the cervix (abstract]. Proc Am Assoc Cancer Res 1994; 35: 234.
37. Sugiyama T, Takeuchi S, Noda K, Yakushiji M. CPT-11 Study Group on Gynecologic Malignancy Phase I study of innotecan (CPT-11) in combination with cisplatin (CDDP) on cervical carcinoma [abstract] Proc Am Soc Clin Oncol 1994; 13: 268.
38. Wagener DJ, Verdonk HE, Dirix LY, et al. Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC early clinical thals group study (see comments]. Ann Oncol 1995; 6: 129-132.
39. Kambe M, Wakui A, Nakao I, et al. A late Phase II study of irinotecan (CPT-11) in patients with advanced gastric cancer [abstract]. Proc Am Soc Clin Oncol 1993; 12: 198.